AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Limited Shareholders
AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - May 6, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) alleging that the Company violated federal securities laws.
纽约，纽约--(Newsfile Corp.-2022年5月6日)-克莱恩律师事务所宣布，已代表奥里尼亚制药公司(纳斯达克代码：AUPH)的股东提起集体诉讼，指控该公司违反了联邦证券法。
Class Period: May 7, 2021 to February 25, 2022
上课时间：2021年5月7日至2022年2月25日
Lead Plaintiff Deadline: June 14, 2022
首席原告截止日期：2022年6月14日
No obligation or cost to you.
对你来说没有义务也没有成本。
Learn more about your recoverable losses in AUPH:
了解有关您在AUPH中可追回损失的更多信息：
Aurinia Pharmaceuticals Inc. NEWS - AUPH NEWS
Auinia制药公司新闻-AUPH新闻
CLASS ACTION CASE DETAILS: The filed complaint alleges that Aurinia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
集体诉讼案例详情：起诉书称，aurinia PharmPharmticals Inc.作出了重大虚假和/或误导性陈述和/或未能披露：(I)aurinia正在经历收入下降；(Ii)aurinia对该公司唯一用于治疗成人活动性狼疮性肾炎的产品LUPKYNIS的2022年销售前景将远远低于预期；(Iii)因此，公司严重夸大了LUPKYNIS的商业前景；(Iv)因此，公司夸大了其财务状况和/或2022年的前景；及(V)因此，本公司的公开声明在所有相关时间均属重大虚假及误导性陈述。
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Aurinia Pharmaceuticals Inc. you have until June 14, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
作为股东，这对你意味着什么：如果你在aurinia PharmPharmticals Inc.蒙受了损失，你可以在2022年6月14日向法院申请主要原告身份。你有能力分享任何赔偿，并不需要你担任主要原告。
NO COST TO YOU: If you purchased Aurinia Pharmaceuticals Inc. securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
您无需支付任何费用：如果您在相关期间购买了aurinia PharmPharmticals Inc.的证券，您可能有权获得补偿，而无需支付任何自付费用。
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the AUPH lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.
如何保护您的财务利益：有关AUPH诉讼的更多信息，请联系Esq的J.Klein。请致电212-616-4899或点击此链接。
ABOUT KLEIN LAW FIRM
关于克莱恩律师事务所
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
J.Klein，Esq.在全国范围内代表投资者并参与涉及金融欺诈的证券诉讼。Klein律师事务所是一家精品诉讼公司，在证券法、公司融资和商业诉讼等广泛领域拥有丰富的经验。自2011年以来，我们经验丰富的律师以个性化的关注为我们的客户取得了卓越的业绩。律师广告。以前的结果并不能保证类似的结果。
CONTACT:
联系方式：
J. Klein, Esq.
J.Klein，Esq.
Empire State Building
帝国大厦
350 Fifth Avenue
第五大道350号
59th Floor
59楼
New York, NY 10118
纽约州纽约市，邮编：10118
jk@kleinstocklaw.com
邮箱：jk@kleinstocklaw.com
Telephone: (212) 616-4899
电话：(212)616-4899
Fax: (347) 558-9665
传真：(347)558-9665
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问
COMTEX_406809237/2523/2022-05-06T19:09:50
COMETX_406809237/2523-05-06T19：09：50
译文内容由第三方软件翻译。